<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125952">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765374</url>
  </required_header>
  <id_info>
    <org_study_id>2010/081/HP</org_study_id>
    <nct_id>NCT01765374</nct_id>
  </id_info>
  <brief_title>Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis</brief_title>
  <acronym>SEWORRA</acronym>
  <official_title>Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To detect by sonography relapse of disease activity prior to clinical symptoms in RA
      patients treated by rituximab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>global score of power-doppler activity measured by ultrasonography on 12 joints</measure>
    <time_frame>at 6 months after initiation of rituximab and then every 2 month over the follow-up period (18 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each time point will be assessed since the main objective of the study is to detect the time of sonographic relapse prior to clinical relapse</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESAOTE MyLab60</intervention_name>
    <description>US evaluation at different time points</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>sonography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  failure to at least one TNF-blocking agent

        Exclusion Criteria:

          -  pregnant or childbearing woman

          -  Rituximab contraindication

          -  woman unable to use contraceptive means
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Vittecoq, MD,PHD</last_name>
    <phone>+33 2 32 88 90 19</phone>
    <email>olivier.vittecoq@chu-rouen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Rheumatology, CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marcelli, MD</last_name>
      <phone>33 2 31 06 31 06</phone>
      <email>marcelli-c@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Normandy</name>
      <address>
        <city>Caen, Le Havre, Rouen, Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology</name>
      <address>
        <city>Le Havre</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Zarnitsky</last_name>
      <phone>33 2 32 73 32 32</phone>
      <email>czarnitsky@ch-havre.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of rheumatology</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Vittecoq, MD,PhD</last_name>
      <phone>33 2 32 88 90 19</phone>
      <email>olivier.vittecoq@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology CHG Elbeuf</name>
      <address>
        <city>Saint Aubin Les Elbeuf</city>
        <zip>76410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frenando da Silva, MD</last_name>
      <phone>33 2 32 96 35 35</phone>
      <email>fernando.dasilva@chi-elbeuf-louviers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>May 12, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rituximab</keyword>
  <keyword>sonography</keyword>
  <keyword>clinical response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
